Regeneus Ltd Stock Market Press Releases and Company Profile
Presentation for AusBiotech 2018
Presentation for AusBiotech 2018

Sydney, Oct 31, 2018 AEST (ABN Newswire) - Regeneus Ltd (googlechartASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

The annual AusBiotech conference brings together Australian and international biotech leaders and stakeholders. For more than three decades, the event has created a forum to reflect on the sector's achievements and exchange ideas to further advance the sector's standing both nationally and globally. AusBiotech is dedicated to consolidating this growth.

John Martin was invited to present as part of the Regenerative Medicine Stream. His session will focus on the successful translation and commercialisation of novel regenerative medicines by Australian companies. MTPConnect, the Australian Government's medtech and pharma growth centre, launched a report entitled 'Regenerative Medicine: Opportunities for Australia' at the beginning of the session. The report was produced in collaboration with AusBiotech's Regenerative Medicine Advisory Group, of which John Martin is a member, as well as other key stakeholders from industry and the research sector.

The following are specific details regarding Regeneus' presentation:

Event: AusBiotech 2018

Date: 31 October 2018

Time: 2.30pm (AEST)

Location: Room 2, Brisbane Convention and Exhibition Centre, Southbank, Brisbane

To view the presentation, please visit:
http://abnnewswire.net/lnk/9BUV0K66


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

https://plus.google.com/108721050557390681250 https://twitter.com/Regeneus https://www.facebook.com/pages/Regeneus/110433905646491 https://www.youtube.com/user/Regeneus http://www.linkedin.com/company/regeneus-ltd?trk=top_nav_home abnnewswire.com 


Contact

Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61-2-9499-8010
E: investors@regeneus.com.au

Media
Imogen Conyers
Media and Capital Partners
T: +61-405-191-257
E: imogen.conyers@mcpartners.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 7) (Last 30 Days: 32) (Since Published: 5914)